The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
This distinction between true value and value traps can challenge even the most skilled investors. Luckily for you, we started StockStory to help you uncover exceptional companies. Keeping that in mind, here is one value stock with strong fundamentals and two best left ignored.
Two Value Stocks to Sell:
Option Care Health (OPCH)
Forward P/E Ratio: 12.1x
With a nationwide network of 177 locations serving 43 states and a team of over 4,500 clinicians, Option Care Health (NASDAQ:OPCH) is the largest independent provider of home and alternate site infusion services, delivering medications and clinical support to patients across the United States.
Why Does OPCH Give Us Pause?
-
Estimated sales growth of 4.3% for the next 12 months implies demand will slow from its two-year trend
-
Free cash flow margin has stayed in place over the last five years
-
Returns on capital haven’t budged, indicating management couldn’t drive additional value creation
Option Care Health’s stock price of $23.90 implies a valuation ratio of 12.1x forward P/E. Read our free research report to see why you should think twice about including OPCH in your portfolio, it’s free.
Diebold Nixdorf (DBD)
Forward P/E Ratio: 10.6x
With roots dating back to 1859 and a presence in over 100 countries, Diebold Nixdorf (NYSE:DBD) provides automated self-service technology, software, and services that help banks and retailers digitize their customer transactions.
Why Should You Sell DBD?
-
Sales stagnated over the last five years and signal the need for new growth strategies
-
Falling earnings per share over the last two years has some investors worried as stock prices ultimately follow EPS over the long term
-
Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
At $67.31 per share, Diebold Nixdorf trades at 10.6x forward P/E. Check out our free in-depth research report to learn more about why DBD doesn’t pass our bar.
One Value Stock to Watch:
JBT Marel (JBTM)
Forward P/E Ratio: 13.8x
Tracing back to its invention of the mechanical milk bottle filler in 1884, JBT Marel (NYSE:JBTM) designs, manufactures, and sells equipment used for food processing and aviation.
Why Do We Like JBTM?
-
Impressive 54.6% annual revenue growth over the last two years indicates it’s winning market share this cycle
-
Healthy unit economics are reflected in its 35.4% gross margin and give it more money to invest in marketing and R&D
-
Earnings per share grew by 30% annually over the last two years, massively outpacing its peers
